GASTROQUIN ACUTE

Informazioni principali

  • Nome commerciale:
  • GASTROQUIN ACUTE
  • Forma farmaceutica:
  • Orale
  • Confezione:
  • 8 iniettori in plastica da 60 ml.
  • Tipo di ricetta:
  • Libera vendita
  • Utilizzare per:
  • Animali
  • Tipo di medicina:
  • Nutrizionale

Documenti

  • per il pubblico:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per il pubblico.

Localizzazione

  • Disponibile in:
  • GASTROQUIN ACUTE
    Italia
  • Lingua:
  • italiano

Informazioni terapeutiche

  • Gruppo terapeutico:
  • Equidi non destinati alla produzione alimenti
  • Area terapeutica:
  • Tutti gli altri prodotti non terapeutici
  • Indicazioni terapeutiche:
  • In caso di rischio di disturbi digestivi (diarrea) e periodi nei quali tali disturbi sono presenti. Stabilizza il bilancio idrico ed elettrolitico per favorire la digestione fisiologica.
  • Dettagli prodotto:
  • Posologia: Durante i primi due mesi di vita, ai puledri sono somministrati 2 x 15 ml di Gastroquin acute/giorno. Ai puledri più grandi sono somministrati 4x 15 ml di Gastroquin acute/giorno. Periodo d'impiego raccomandato: 1-7 giorni.

Altre informazioni

Status

  • Fonte:
  • Ministero della Salute - Italia
  • Numero dell'autorizzazione:
  • 20899
  • Ultimo aggiornamento:
  • 14-08-2017

Riassunto delle caratteristiche del prodotto: dosaggio, interazioni, effetti collaterali

Gastroquin acute

RITROVA L´EQUILIBRIO

For more information:

www.derbymed.eu

For more information:

www.derbymed.eu

Per maggiori informazioni:

www.derbymed.eu

Per maggiori informazioni:

www.derbymed.eu

Può essere utilizzato come profilassi o durante

o dopo periodi di disturbi digestivi.

Per stabilizzare l’acqua e

l’equilibro elettrolitico

Supporta il ritorno alla

normale consistenza

degli escrementi

Lega le tossine

derbymed è un marchio esclusivo di

RITROVA L´EQUILIBRIO

Distribuito per l’Italia da:

Industria Italiana Integratori TREI S.p.A.

IT000013RE

Stabilimento produttivo: Via Affarosa, 4 - 42010 Rio Saliceto (RE)

www.treivet.com

STOP

Composizione per kg

Oli e grassi vegetali di girasole 54,3 %, destrosio* 8,0 %,

lievito (anidro) 8,0 %, cloruro di sodio 4,0 %, cloruro di

potassio 2,4 %

*fonte di carboidrati facilmente disponibile

Componenti analitici % s.t.q.

Proteina grezza 3,5 %, Oli e grassi grezzi 58,6 %.

Cellulosa grezza 0,2 %, Ceneri grezze 11,5 %,

Sodio 1,5 %, Potassio 1,3 % Cloruri 3,5 %

Additivi per kg

Additivi nutrizionali: Vitamina E (tutto-rac-α-tocoferile acetato, 3a 700) 1000 mg, Vitamina B1

(Cloridrato di tiamina) 400 mg, Vitamina B2 (Cianocobalamina) 400 mg, Vitamina B6 (Cloridrato di

piridossina, 3a 831) 100 mg, Vitamina B12 (Cianocobalamina) 5000 mcg

Stabilizzatori della flora intestinale: Saccharomyces cerevisiae (NCYC Sc 47) (Actisaf) (4b1702)

200 x 10(9) CFU/kg

Additivi organolettici: Estratto di Castagno 100000 mg

Gastroquin acute

Istruzioni per l’uso

In caso di problemi digestivi (diarrea) durante i primi due mesi

di vita somministrare ai puledri 2 x 15 ml di Gastroquin acute al

giorno. Ai puledri più grandi e cavalli adulti somministrare

4 x 15 ml di Gastroquin acute al giorno.

Periodo d’impiego consigliato: 1–7 giorni

Per maggiori informazioni:

www.derbymed.eu

Per maggiori informazioni:

www.derbymed.eu

Integratore alimentare per stabilizzare l’acqua e l’equilibrio elettrolitico e per arrestare la diarrea

Gastroquin acute contiene una miscela di agenti astringenti intestinali pro e prebiotici per stabilizzare la consistenza degli

escrementi, mannani e

-glucani. Gastroquine acute stimola l’attivazione biologica del sistema immunitario.

Il probiotico NCYC Sc 47 e i tannini del castagno stimolano un miglioramento nell’assorbimento dell’acqua a livello del colon e della

flora intestinale. Gastroquin acute permette di reintegrare le vitamine e gli elettroliti persi durante i periodi di diarrea.

INFORMAZIONI PRODOTTO

INFORMAZIONI PRODOTTO

02-2016

Distribuito per l’Italia da:

Industria Italiana Integratori TREI S.p.A.

IT000013RE

Stabilimento produttivo: Via Affarosa, 4 - 42010 Rio Saliceto (RE)

www.treivet.com

  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.

    Richiedi il foglio illustrativo per il pubblico.



  • Documenti in altre lingue sono disponibili qui

28-11-2018

FDA approves treatment for adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a certain genetic mutation

FDA approves treatment for adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a certain genetic mutation

The FDA approved Xospata (gilteritinib) tablets for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.

FDA - U.S. Food and Drug Administration

28-11-2018

Bruins doet voorstellen om de keten van acute zorg te versterken

Bruins doet voorstellen om de keten van acute zorg te versterken

Het concept van de Algemene Maatregel van Bestuur voor de acute zorg in de regio is door Minister Bruno Bruins voor Medische Zorg en Sport naar de Tweede Kamer gestuurd. Hierin worden verschillende voorstellen gedaan om de keten van acute zorg in de regio te versterken door voorwaarden te stellen aan de regionale samenwerking en afstemming hierover in alle regio’s (11 in Nederland).

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

22-11-2018

Safety and efficacy of Monteban® G100 (narasin) for ducks for fattening

Safety and efficacy of Monteban® G100 (narasin) for ducks for fattening

Published on: Wed, 21 Nov 2018 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of Monteban® G100 for ducks. Monteban® G100, containing narasin, is intended for the prevention of coccidiosis in ducks for fattening at a dose range of 60–70 mg/kg of complete feed. Narasin from Monteban® G100 is safe for ducks for fattening at a level of 70 mg/kg complete feed...

Europe - EFSA - European Food Safety Authority Publications

21-11-2018

FDA approves new treatment for patients with acute myeloid leukemia

FDA approves new treatment for patients with acute myeloid leukemia

The FDA approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy.

FDA - U.S. Food and Drug Administration

16-11-2018

Evaluation of confirmatory data following the Article 12 MRL review for pyraclostrobin

Evaluation of confirmatory data following the Article 12 MRL review for pyraclostrobin

Published on: Thu, 15 Nov 2018 The applicant BASF SE submitted a request to the competent national authority in Germany to evaluate the confirmatory data that were identified for pyraclostrobin in the framework of the MRL review under Article 12 of Regulation (EC) No 396/2005 as not available. To address the data gaps, residues trials supporting the existing use of pyraclostrobin on table grapes authorised in southern EU Member States and an analytical method for analysing residues of pyraclostrobin in ...

Europe - EFSA - European Food Safety Authority Publications

24-10-2018

FDA approves new drug to treat influenza

FDA approves new drug to treat influenza

FDA approved Xofluza (baloxavir marboxil) to treat acute uncomplicated flu in patients 12 years old and older who have been symptomatic for less than 48 hours.

FDA - U.S. Food and Drug Administration

28-9-2018

FDA authorizes first next generation sequencing-based test to detect very low levels of remaining cancer cells in patients with acute lymphoblastic leukemia or multiple myeloma

FDA authorizes first next generation sequencing-based test to detect very low levels of remaining cancer cells in patients with acute lymphoblastic leukemia or multiple myeloma

FDA authorizes first next generation sequencing-based test to detect very low levels of remaining cancer cells in patients with acute lymphoblastic leukemia or multiple myeloma

FDA - U.S. Food and Drug Administration

14-9-2018

FDA approves device for treatment of acute coronary artery perforations

FDA approves device for treatment of acute coronary artery perforations

FDA approves device for treatment of acute coronary artery perforations

FDA - U.S. Food and Drug Administration

29-8-2018

Review of the existing maximum residue levels for prochloraz according to Article 12 of Regulation (EC) No 396/2005

Review of the existing maximum residue levels for prochloraz according to Article 12 of Regulation (EC) No 396/2005

Published on: Mon, 27 Aug 2018 00:00:00 +0200 According to Article 12 of Regulation (EC) No 396/2005, EFSA has reviewed the maximum residue levels (MRLs) currently established at European level for the pesticide active substance prochloraz. To assess the occurrence of prochloraz residues in plants, processed commodities, rotational crops and livestock, EFSA considered the conclusions derived in the framework of Directive 91/414/EEC, the MRLs established by the Codex Alimentarius Commission as well as th...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Risk to human and animal health related to the presence of 4,15‐diacetoxyscirpenol in food and feed

Risk to human and animal health related to the presence of 4,15‐diacetoxyscirpenol in food and feed

Published on: Thu, 16 Aug 2018 00:00:00 +0200 4,15‐Diacetoxyscirpenol (DAS) is a mycotoxin primarily produced by Fusarium fungi and occurring predominantly in cereal grains. As requested by the European Commission, the EFSA Panel on Contaminants in the Food Chain (CONTAM) assessed the risk of DAS to human and animal health related to its presence in food and feed. Very limited information was available on toxicity and on toxicokinetics in experimental and farm animals. Due to the limitations in the avai...

Europe - EFSA - European Food Safety Authority Publications

20-7-2018

FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation

FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation

FDA approves new drug for the treatment of adults with acute myeloid leukemia who have a specific genetic mutation and a companion diagnostic to detect specific mutations in the IDH1 gene in patients with AML

FDA - U.S. Food and Drug Administration

18-7-2018

Orphan designation:  Azacitidine,  for the: Treatment of acute myeloid leukaemia

Orphan designation: Azacitidine, for the: Treatment of acute myeloid leukaemia

Europe - EMA - European Medicines Agency

13-6-2018

Orphan designation:  Ivosidenib,  for the: Treatment of acute myeloid leukaemia

Orphan designation: Ivosidenib, for the: Treatment of acute myeloid leukaemia

Europe - EMA - European Medicines Agency

29-5-2018

Orphan designation:  Midostaurin,  for the: Treatment of acute myeloid leukaemia

Orphan designation: Midostaurin, for the: Treatment of acute myeloid leukaemia

Europe - EMA - European Medicines Agency

29-5-2018

Orphan designation:  Venetoclax,  for the: Treatment of acute myeloid leukaemia

Orphan designation: Venetoclax, for the: Treatment of acute myeloid leukaemia

Europe - EMA - European Medicines Agency

10-5-2018

Medline Remedy Essentials No-Rinse Cleansing Foam: Avoid Using - Multistate Outbreak of Burkholderia Cepacia Complex

Medline Remedy Essentials No-Rinse Cleansing Foam: Avoid Using - Multistate Outbreak of Burkholderia Cepacia Complex

CDC reports that there are 10 confirmed cases of infection caused by bacteria within the Burkholderia cepacia complex, also commonly called B. cepacia, in three states: California (2), Pennsylvania (7), and New Jersey (1). These patients were already hospitalized for acute conditions and acquired the infections while hospitalized. The infections have been linked to the Medline product, Remedy Essentials No-Rinse Cleansing Foam.

FDA - U.S. Food and Drug Administration

6-4-2017

More batches of EpiPen® are withdrawn

More batches of EpiPen® are withdrawn

MEDA has decided to withdraw four more batches of EpiPen®. The withdrawal concerns two batches of EpiPen® 300 micrograms/dose and two batches of EpiPen® Jr 150 micrograms/dose. The latter is used for acute hypersensitivity reactions in children. The reason for the withdrawal is that there is a risk that the auto-injector does not work.

Danish Medicines Agency

19-12-2018


Orphan designation: 1-(2-hydroxyethyl)-8-{[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy) phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide fumarate salt, Treatment of acute myeloid leukaemia, 24/08/2018, Positive

Orphan designation: 1-(2-hydroxyethyl)-8-{[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy) phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide fumarate salt, Treatment of acute myeloid leukaemia, 24/08/2018, Positive

Orphan designation: 1-(2-hydroxyethyl)-8-{[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy) phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide fumarate salt, Treatment of acute myeloid leukaemia, 24/08/2018, Positive

Europe - EMA - European Medicines Agency

19-12-2018


Orphan designation: melatonin, Treatment of acute radiation syndrome, 26/10/2018, Positive

Orphan designation: melatonin, Treatment of acute radiation syndrome, 26/10/2018, Positive

Orphan designation: melatonin, Treatment of acute radiation syndrome, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

18-12-2018


Orphan designation: Mercaptopurine (oral suspension), Treatment of acute lymphoblastic leukaemia, 30/04/2009, Positive

Orphan designation: Mercaptopurine (oral suspension), Treatment of acute lymphoblastic leukaemia, 30/04/2009, Positive

Orphan designation: Mercaptopurine (oral suspension), Treatment of acute lymphoblastic leukaemia, 30/04/2009, Positive

Europe - EMA - European Medicines Agency

14-9-2018

#FDA approves device for treatment of acute coronary artery perforations. Read more about the approval here:  https://go.usa.gov/xPgTA  #MedicalDevice

#FDA approves device for treatment of acute coronary artery perforations. Read more about the approval here: https://go.usa.gov/xPgTA  #MedicalDevice

#FDA approves device for treatment of acute coronary artery perforations. Read more about the approval here: https://go.usa.gov/xPgTA  #MedicalDevice

FDA - U.S. Food and Drug Administration

9-7-2018

Scientific guideline:  Concept paper on the need to develop a reflection paper on development of medicinal products to prevent and treat acute kidney injury, draft: consultation open

Scientific guideline: Concept paper on the need to develop a reflection paper on development of medicinal products to prevent and treat acute kidney injury, draft: consultation open

The concept paper will include discussion of and recommendations for the requirements for evaluation and development of medicinal products for the prevention and/or treatment of acute kidney injury (AKI) and its long-term complications. Relevant topics for discussion include patient populations, endpoints, study methodology, and study duration.

Europe - EMA - European Medicines Agency